Trevena's Phase II Pain Drug Bests Morphine
This article was originally published in Scrip
Trevena Inc.'s stock shot up this week on the news its post-operative pain drug met primary endpoints in a Phase IIb study – showing superiority over morphine.
You may also be interested in...
A mixed bag of safety results for the new opioid Olinvo (oliceridine) in the Phase III APOLLO pain trials disappoints the market, but analysts are encouraged by the totality of the data and optimistic about approval.
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.